Unlocking Insights
in CLL
CLL Dataset Insights
Our dataset* provides valuable insights into CLL, including but not limited to:
+800
Estimated N CLL Patients
10.5%
Average 1 year mortality %
6.2
years
Mean FU period
48
visits
Average visits per patient
44.9%
% Patients BTKI* treatment
74.8
years
Average age at diagnosis
452
Endpoints
* Bruton Tyrosine Kinase Inhibitor
Note that the estimated patient counts provided (prior to inclusion/exclusion criteria) are specific to our Belgian dataset. Details on the representativeness and diversity of the Belgian dataset for global studies can be found above. The LynxCare datasets continue to expand, encompassing real-world data from hospitals across Europe. Complete the form on the right to gain further details and to discuss your study needs with one of our RWE experts.
Closing the Gap
The Value of Unstructured Data in the CLL Pathway
Structured vs. Unstructured
Structured data alone only provides part of the picture, missing key nuances.Combining structured data with rich EHR narrative datacan improve our understanding of CLL pathophysiology andoutcomes, as evidenced by our data which yielded a higher morbidity index of 34% compared to 28% with structured data alone.
RCT vs. RWE
In the era of small molecule inhibitor targeted therapies, the landscape of chronic lymphocytic leukemia (CLL) has undergone a breathtaking transformation. While randomized controlled trials(RCTs) remain the gold standard, they are often unable to keep pace with the clinical questions that arise during the use of novel agents.
Real-World Insights
Using our federated real-world dataset, we can analyze adverse events, OS, and treatment patterns in real time, providing invaluable insights into the patient pathway of CLL.
Unpacking The Data
The Sources Behind Our Insights
Unlock Research Questions
Our dataset offers life science companies unparalleled insights into the relationship between specific biomarkers, comorbidities, and treatment outcomes in CLL.
Research Question/ Endpoints
Demographics
Cancer type
Histology
Comorbidities
Lab results
Cancer treatment
Hospital visit & admissions
Survival
Biomarkers
Genetic drivers
Outcomes
Adverse events
Complications
Titration / Dosing
Treatment dynamics
Incidence & Prevalence
Adherence
Efficacy
Indication split
Safety profile
How Pharma Can Leverage LynxCare's Dataset
Clinical Trial Design
Our granular and quality-controlled real-world dataset can help design clinical trials that better reflect real-world scenarios.
Synthetic Control Arm
Our dataset can be used to create synthetic control arms, which can be used to evaluate the effectiveness of new treatments.
Market Access
Our dataset can help pharma companies gain a better understanding of the market and generate granular value dossiers for HEOR.
Medical Affairs
Our dataset can help medical affairs teams better understand the clinical outcomes and real-world evidence associated with their products.
How Hospitals Can Benefit from a LynxCare Database
Improving Patient Care
Find more relevant medical information thanks to LynxCare's disease-specific NLP pipeline for a better patient and population understanding.
Research & Network Opportunities
Initiate or participate in national and international multi-center, multi-country RWE studies.
Benefit from network of KOLs.
Scientific Research
Initiate or participate in (pharma- or physician initiated) peer-reviewed (multi-center, multi-country) publications
Increased Clinical Trial Participation
More effective patients/cohort selection through clinical NLP, enrolling more patients in clinical trials
Improve your Data Quality
Receive feedback on the clinical data quality of your hospital’s database.
Benefit from data science training provided
World-Class Expertise.
The LynxCare Advantage
Differentiating factors from other NLP providers & established RWD vendors
Building Trust
Quality Control and Data Freshness
Quality Control
Data Freshness
OMOP CDM Data Warehouse
Patient Insights
More Than Numbers
Individualized Care
Cross-Disciplinary Collaboration
Impact on Patient Outcomes
The Future of CLL Treatment
How LynxCare Can Help
Personalized Medicine
With our comprehensive dataset and world-class expertise, LynxCare is well-positioned to help clinicians tailor treatments to specific patient needs, opening up the possibility of personalized medicine for CLL. Our data asset provides valuable insights into individual pathways of CLL patients, enabling clinicians to make more informed treatment decisions.
Improved Outcomes
Our data asset aims to ultimately improve patient outcomes by providing insights into the clinical pathway of CLL patients. By analysing real-world patient data, our dataset offers a unique perspective on the effectiveness and safety of different treatments. This information can help clinicians make more informed treatment decisions, leading to better outcomes for patients.
Continued Innovation
LynxCare is committed to driving innovation in CLL treatment and management. With our world-class expertise in data analysis and interpretation, we aim to continue to provide valuable insights and solutions to healthcare providers and researchers. Our comprehensive dataset offers a wealth of information for life science companies and other stakeholders interested in advancing CLL therapy.
